ArticleCancer medicine2023

The association between body mass index and efficacy of pembrolizumab as second-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Xinyi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.